STOCK TITAN
  1. Home
  2. News
  3. TAK

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of - TAK STOCK NEWS

Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.

Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.

With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.

Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.

Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.

Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.

News

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) has received FDA approval for FRUZAQLA™, a targeted therapy for metastatic colorectal cancer. FRUZAQLA demonstrated significant improvements in overall survival and progression free survival in two Phase 3 clinical trials. This approval marks the first novel chemotherapy-free treatment option for mCRC patients in the U.S. in over a decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
fda approval
-
News

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

Rhea-AI Summary
Takeda announces positive results from a Phase 2b trial evaluating TAK-279 for the treatment of psoriatic arthritis, with the drug meeting its primary endpoint and demonstrating improvements in key secondary endpoints. The company plans to initiate Phase 3 studies in plaque psoriasis and psoriatic arthritis, while exploring TAK-279 in other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
clinical trial
-
News

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Rhea-AI Summary
Takeda announces financial results for the first half of fiscal year 2023, reporting revenue growth of +6.4% at AER and +1.4% at CER. Core operating profit decreased by -9.5% at CER. Full-year revenue and core EPS forecasts have been raised, while full-year profit forecasts have been lowered. No change to free cash flow outlook or management guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.72%
Tags
none
News

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Rhea-AI Summary
Takeda's ADCETRIS receives European Commission approval for the treatment of previously untreated CD30+ Stage III Hodgkin lymphoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
News

Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

Rhea-AI Summary
Takeda settles tax assessment with Irish Revenue for EUR 130 million, resulting in a tax expense reduction of approximately JPY 63 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
News

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas

Rhea-AI Summary
Takeda's Phase 3 study for Alofisel in treating Crohn's Perianal Fistulas does not meet primary endpoint
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
clinical trial
News

Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years

Rhea-AI Summary
The World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) has shared recommendations for the use of Takeda's QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) in public vaccination programs. The vaccine should be considered for introduction in settings with high dengue disease burden and high transmission intensity. It should be introduced to children aged 6 to 16 years and administered in a 2-dose schedule with a 3-month interval between doses. The vaccine has shown 80.2% efficacy at 12-months follow-up and 90.4% efficacy in preventing hospitalization due to dengue fever. QDENGA has been generally well tolerated with no identified safety risks. It is currently available in the private market in some countries and will soon be available in Argentina and Thailand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
News

Takeda Provides Update on EXKIVITY® (mobocertinib)

Rhea-AI Summary
Takeda announces voluntary withdrawal of EXKIVITY for lung cancer treatment in the US and globally due to trial results not meeting primary endpoint.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
-
News

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Rhea-AI Summary
FDA approves subcutaneous administration of ENTYVIO for ulcerative colitis maintenance therapy, providing patients and physicians with more flexibility. ENTYVIO SC demonstrated a statistically significant proportion of patients achieving clinical remission compared to placebo. Takeda does not expect a material impact on the full year forecast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
fda approval
News

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Rhea-AI Summary
Takeda receives approval for CUVITRU in Japan for patients with agammaglobulinemia or hypogammaglobulinemia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none

FAQ

What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is $13.1 as of December 20, 2024.

What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is approximately 41.4B.

What are Takeda Pharmaceutical's core therapeutic areas?

Takeda focuses on oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

Where is Takeda Pharmaceutical headquartered?

Takeda is headquartered in Tokyo, Japan.

What recent collaborations has Takeda Pharmaceutical entered into?

Takeda recently entered a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation to incubate early drug discovery programs.

How diversified is Takeda's revenue geographically?

Takeda's revenue is geographically diversified: 50% from the US, 20% from Japan, and 20% from Europe and Canada.

What was Takeda's revenue in fiscal 2023?

Takeda's revenue in fiscal 2023 was JPY 4.3 trillion.

Who can benefit from Takeda's new drug NBI-1065845?

NBI-1065845 is targeted at patients with major depressive disorder who have not benefited from at least one existing antidepressant treatment.

What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?

The joint venture focuses on incubating early drug discovery programs to advance academic discoveries into practical medical treatments.

How long has Takeda been in the pharmaceutical industry?

Takeda has been a leader in the pharmaceutical industry for over two centuries.

In how many countries does Takeda operate?

Takeda operates in approximately 80 countries.

How does Takeda contribute to the field of major depressive disorder treatment?

Takeda collaborates with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment showing positive Phase 2 results for MDD.

Stock TAK logo
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of

NYSE:TAK

TAK Rankings

#312 Ranked by Market Cap
#591 Ranked by Dividends

TAK Stock Data

41.37B
3.17B
0.01%
2.45%
0.18%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tokyo